替比夫定初治慢性乙型肝炎患者疗效与安全性观察

谢榕; 江建宁; 苏明华; 刘志红; 钟少华; 何丽霞; 梁延秀; 胡家光; 黄小红; 郭稳稳; 符武岛; 祝美琴; 王保健

替比夫定初治慢性乙型肝炎患者疗效与安全性观察

广西医科大学第一附属医院

基金项目:

广西自然科学基金(2010GXNSFD013046、桂科自0832117、桂科自0542092,桂科青0832037)；广西医学科学实验中心开放基金(KFJJ2010-20)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2133
- HTML全文浏览量: 23
- PDF下载量: 638
- 被引次数: 0
出版历程
- 出版日期: 2012-06-20

Efficacy and safety of initial telbivudine treatment in chronic hepatitis B patients

Research funding:

摘要

摘要: 目的分析HBeAg阳性、阴性慢性乙型肝炎（CHB）患者初次使用替比夫定的疗效及安全性。方法 73例CHB患者（HBeAg阳性50例,阴性23例）,接受替比夫定治疗至少1年,于治疗基线、病毒学应答前每个月、病毒学应答后每3个月检测HBV DNA、ALT、HBV血清标志物,观察治疗期间累计病毒学应答率、血清学转换率和耐药率;分析12、24周HBeAg下降幅度对预测血清学转换的价值;根据患者的情况不定期检测肌酸激酶（CK）。结果（1）HBeAg阳性、阴性累计病毒学应答率1年分别为96%、100%,2年分别为96%、100%,其中90%HBeAg阳性、95%阴性患者在24周获得病毒学应答;（2）HBeAg阳性者1、2年累计血清学转换率分别为48%、61%;（3）HBeAg阳性、阴性累计耐药率1年分别为2%、4%,2年分别为24%、11%;（4）12、24周HBeAg下降幅度预测血清学转换的cut-off值分别为0.2557、0.3844log PEIU/ml,12周HBeAg下降幅度≥0.2557log PEIU/ml、24周≥0.3844log PEIU/ml的患者较低于该值者2年累计血清...
- 肝炎,乙型,慢性 /
- 抗病毒药 /
- 替比夫定 /
- 治疗
Abstract: Objective To analyze the efficacy and safety of initial telbivudine treatment in chronic hepatitis B (CHB) patients.Methods Seventy-three consecutive CHB patients treated with initial telbivudine treatment for at least one year were enrolled in the study between September 2007 and February 2012.Measurements were made of alanine aminotransferase (ALT) , hepatitis B virus (HBV) DNA, and HBV serological markers at baseline, then every month before virological response (HBV DNA<1.0×103 copies/ml) was reached, and every three months after virological response.The cumulative rate of virological response, hepatitis B e antigen (HBeAg) conversion, and resistance were calculated.The value of the HBeAg (PEIU/ml) descending amplitude (log) for predicting HBeAg conversion at 12 and 24 weeks was evaluated.Creatine kinase (CK) levels were measured at intervals according to the patient condition.Results Of the 73 CHB cases, 50 were HBeAg-positive and 23 were HBeAg-negative.The cumulative rate of virological response within one year of treatment was 96% in the HBeAg-positive group and 100% in the HBeAg-negative group, and the rate within two years of treatment was 96% in the HBeAg-positive group and 100% in the HBeAg-negative group.Among the patients achieving virological response, 90% in the HBeAg-positive group and 95% in the HBeAg-negative group occurred within 24 weeks.The cumulative rates of HBeAg conversion within one and two years of treatment were 48% and 61%, respectively.The cumulative rates of resistance for the HBeAg-positive group and the HBeAg-negative group were 2% and 4%, respectively, in one year, and 24% and 11%, respectively, in two years.The cutoff values of HBeAg descending amplitude at 12 and 24 weeks for predicting HBeAg conversion were 0.2557 and 0.3844.The cumulative rate of HBeAg conversion in the cases with HBeAg descending amplitude ≥0.2557 log PEIU/ml at 12 weeks and ≥0.3884 log PEIU/ml at 24 weeks were significantly higher than those from the two years group (χ2=28.996 and 15.036, both P<0.0001) .CK was tested in 66 patients (total of 186 times) , and 78.8% of patients were found to have elevated CK.Of those, 95.6% were 1-2 grade, and only 4.4% were ≥3 grade.The elevated CK cases had no obvious signs of myalgia or myitis, and for all the CK level resolved to normal within three to six months.There were no cases of telbivudine termination due to elevated CK.Conclusion Telbivudine is an effective and safe drug for initial treatment of CHB patients, regardless of HBeAg status.The descending amplitude (log) of HBeAg at 12 and 24 weeks of telbivudine treatment can be a good predictive factor for one and two year HBeAg conversion.
- hepatitis B /
- chronic /
- antiviral agents /
- telbivudine

HTML全文

参考文献(8)

[1]张文宏, 翁心华, 庄辉, 等.专家解读《慢性乙型肝炎防治指南》[J].中国病原生物学杂志, 2006, 1 (2) :附页3-4.

[2] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-XVI.

[3]张文宏, 翁心华, 庄辉.《慢性乙型肝炎防治指南》专家讨论会纪要[J].中华肝脏病杂志, 2006, 14 (5) :390-392.

[4]Liaw YF, Gane E, Leung N, et al.2-Year GLOBE trial results:telbivudine Is superior to lamivudine in patients with chronic hepati-tis B[J].Gastroenterology, 2009, 136 (2) :486-495.

[5]Seto WK, Lai CL, Fung J, et al.Significance of HBV DNA levels at12 weeks of telbivudine treatment and the 3 years treatment outcome[J].J Hepatol, 2011, 55 (3) :522-528.

[6]黄晶, 陈小苹, 陈学福, 等.替比夫定和恩替卡韦治疗HBeAg阳性慢性乙型肝炎的疗效及HBeAg血清学转换的预测因素[J].中华肝脏病杂志, 2011, 19 (3) :178-181.

[7]Lai CL, Gane E, Liaw YF, et al.Telbivudine versus lamivudine inpatients with chronic hepatitis B[J].New Eng J Med, 2007, 357 (25) :2576-2588.

[8]Liaw YF, Leung N, Guan R, et al.Asian-Pacific consensus state-ment on the management of chronic hepatitis B:a 2005 update[J].Liver Int, 2005, 25 (3) :472-489.

施引文献

资源附件(0)

访问统计